Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Mauro Magnani, Francesco Graziano et al.|British Journal of Cancer|2017Cited by 68
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Rossana Berardi, Adriana Romiti et al.|European Journal of Cancer|2017Cited by 30
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Giordano Beretta, Sara Lonardi et al.|European Journal of Cancer|2021Cited by 15
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup AnalysisGerardo Rosati, Fabio Galli, Maurizio Cantore et al.|The Oncologist|2020Cited by 11
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE StudyStefania Gori, Fabrizio Nicolis, Alessandra Fabi et al.|Cancers|2023Cited by 9